Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer

被引：0
|
作者：
Yoshinori Munemoto
Mitsuro Kanda
Keiichiro Ishibashi
Taishi Hata
Michiya Kobayashi
Junichi Hasegawa
Mutsumi Fukunaga
Akinori Takagane
Toshio Otsuji
Yasuhiro Miyake
Michitaka Nagase
Junichi Sakamoto
Masaki Matsuoka
Koji Oba
Hideyuki Mishima
机构：
[1] Fukuiken Saiseikai Hospital,Department of Surgery
[2] Nagoya University Graduate School of Medicine,Department of Gastroenterological Surgery (Surgery II)
[3] Saitama Medical Center,Department of Digestive Tract and General Surgery
[4] Saitama Medical University,Department of Gastroenterological Surgery
[5] Osaka University Graduate School of Medicine,Department of Human Health and Medical Sciences
[6] Kochi Medical School,Department of Surgery
[7] Osaka Rosai Hospital,Department of Surgery
[8] Hyogo Prefectural Nishinomiya Hospital,Department of Internal Medicine
[9] Surgical Division,Department of Surgery
[10] Hakodate Goryoukaku Hospital,Department of Surgical Oncology
[11] Dongo Hospital,Department of Biostatistics
[12] Minoh City Hospital Gastrointestinal Research Center,undefined
[13] Gifu University Graduate School of Medicine,undefined
[14] Director,undefined
[15] Tokai Central Hospital,undefined
[16] Matsuoka Clinic,undefined
[17] School of Public Health,undefined
[18] Tokyo University Graduate School of Medicine,undefined
[19] Interfaculty Initiative in Information Studies,undefined
[20] Tokyo University,undefined
[21] Unit of Cancer Center,undefined
[22] Aichi Medical University,undefined
来源：
BMC Cancer | / 15卷
关键词：
Colorectal cancer; Elderly; Bevacizumab; XELOX;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] EFFECTIVENESS OF CHEMOTHERAPY WITH OXALIPLATIN, CAPECITABINE AND BEVACIZUMAB (XELOX plus BEV) IN SECOND LINE THERAPY OF METASTATIC COLORECTAL CANCER (MCRC)
    Arzykulov, Z.
    Chichua, N.
    Smagulova, K.
    Khamidullina, G.
    Mukanova, S.
    Suriya, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 32 - 32
  • [42] Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
    Bazarbashi, Shouki
    Aljubran, Ali
    Alzahrani, Ahmad
    Mohieldin, Ahmed
    Soudy, Hussein
    Shoukri, Mohammed
    CANCER MEDICINE, 2015, 4 (10): : 1505 - 1513
  • [43] Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer
    Cassinello, Javier
    Valero Alvarez, Jose
    Garcia Lopez, Maria Jose
    Pujol, Eduardo
    Colmenarejo, Antonio
    Segovia, Femando
    Marcos, Fernando
    Filipovich, Elena
    Arcediano, Alberto
    Garcia Castro, Ines
    CLINICAL COLORECTAL CANCER, 2006, 5 (06) : 429 - 435
  • [44] An oxaliplatin based regimen in selected patients (PTS) with metastatic colorectal cancer (MCC)
    Borgonovo, Karen
    La Verde, Nicla
    Garassino, Marina Chiara
    Cobelli, Stefano
    Rovej, Rossella
    Perrone, Silvia
    Dimaiuta, Mariastella
    Mihali, Dorian
    Torri, Valter
    Farina, Gabriella
    ANNALS OF ONCOLOGY, 2007, 18 : 170 - 170
  • [45] COI regimen (capecitabine, oxaliplatin, irinotecan) as possible neoadjuvant treatment in metastatic colorectal cancer patients
    Buzzoni, R.
    Bajetta, E.
    Di Bartolomeo, M.
    Ferrario, E.
    Gevorgyan, A.
    Dotti, K. F.
    Mancin, M.
    Platania, M.
    Colombo, A.
    ANNALS OF ONCOLOGY, 2006, 17 : XI39 - XI39
  • [46] Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer
    Emel Yaman
    Aytug Uner
    Ozlem Er
    Ugur Coskun
    Suleyman Buyukberber
    Mustafa Dikilitas
    Mevlude Polat
    Deniz Yamac
    Ali Osman Kaya
    Ramazan Yildiz
    Banu Ozturk
    Mustafa Benekli
    Medical Oncology, 2007, 24 : 431 - 435
  • [47] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab (bev) as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Takada, Kohichi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [48] Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer
    Yaman, Emel
    Uner, Aytug
    Er, Ozlem
    Coskun, Ugur
    Buyukberber, Suleyman
    Dikilitas, Mustafa
    Polat, Mevlude
    Yamac, Deniz
    Kaya, Ali Osman
    Yildiz, Ramazan
    Ozturk, Barm
    Benekli, Mustafa
    MEDICAL ONCOLOGY, 2007, 24 (04) : 431 - 435
  • [49] Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer
    Arkenau, Hendrik-Tobias
    Graeven, Ullrich
    Kubicka, Stephan
    Grothey, Axel
    Englisch-Fritz, Christina
    Kretzschmar, Albrecht
    Greil, Richard
    Freier, Werner
    Seufferlein, Thomas
    Hinke, Axel
    Schmoll, Hans-Joachim
    Schmiegel, Wolff
    Porschen, Rainer
    CLINICAL COLORECTAL CANCER, 2008, 7 (01) : 60 - 64
  • [50] Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
    Cupini, S.
    Bursi, S.
    Masi, G.
    Loupakis, F.
    Barbara, C.
    Barletta, M. T.
    Baldi, G. G.
    Vasile, E.
    Fornaro, L.
    Petrini, I.
    Allegrini, G.
    Antonuzzo, A.
    Di Marsico, R.
    Andreuccetti, M.
    Ricci, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
12345